% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{ChelariuRaicu:300182,
      author       = {A. Chelariu-Raicu$^*$ and T. C. Vu and S. Umamaheswaran and
                      E. Stur and P. Hanjra and Y. Han and M. Hu and J. Lin and B.
                      C. Lawson and J. Liu and A. K. Sood and Y. Wen},
      title        = {{IMGN}853 {I}nduces {A}utophagic {C}ell {D}eath in
                      {C}ombination {T}herapy for {O}varian {C}ancer.},
      journal      = {Cancer research communications},
      volume       = {5},
      number       = {3},
      issn         = {2767-9764},
      address      = {Philadelphia, Pa.},
      publisher    = {American Association for Cancer Research},
      reportid     = {DKFZ-2025-00659},
      pages        = {512 - 526},
      year         = {2025},
      abstract     = {FOLR1 is heterogeneously overexpressed in epithelial
                      ovarian cancer. We examined the combined effects of the
                      anti-FOLR1 antibody-drug conjugate (IMGN853) with other
                      drugs, including topotecan, anti-VEGF-A antibody, and
                      olaparib. These findings could contribute to the continued
                      development of IMGN853 in the treatment of ovarian cancer.},
      keywords     = {Female / Humans / Ovarian Neoplasms: drug therapy / Ovarian
                      Neoplasms: pathology / Autophagy: drug effects /
                      Immunoconjugates: therapeutic use / Immunoconjugates:
                      pharmacology / Antineoplastic Combined Chemotherapy
                      Protocols: pharmacology / Antineoplastic Combined
                      Chemotherapy Protocols: therapeutic use / Cell Line, Tumor /
                      Piperazines: pharmacology / Piperazines: therapeutic use /
                      Piperazines: administration $\&$ dosage / Carcinoma, Ovarian
                      Epithelial: drug therapy / Carcinoma, Ovarian Epithelial:
                      pathology / Topotecan: pharmacology / Topotecan: therapeutic
                      use / Topotecan: administration $\&$ dosage / Folate
                      Receptor 1: metabolism / Folate Receptor 1: genetics /
                      Phthalazines: pharmacology / Phthalazines: therapeutic use /
                      Vascular Endothelial Growth Factor A: metabolism / Animals /
                      Mice / Immunoconjugates (NLM Chemicals) / olaparib (NLM
                      Chemicals) / Piperazines (NLM Chemicals) / Topotecan (NLM
                      Chemicals) / Folate Receptor 1 (NLM Chemicals) /
                      Phthalazines (NLM Chemicals) / FOLR1 protein, human (NLM
                      Chemicals) / Vascular Endothelial Growth Factor A (NLM
                      Chemicals)},
      cin          = {MU01},
      ddc          = {610},
      cid          = {I:(DE-He78)MU01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40029935},
      pmc          = {pmc:PMC11951858},
      doi          = {10.1158/2767-9764.CRC-24-0215},
      url          = {https://inrepo02.dkfz.de/record/300182},
}